Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.41 |
| ▸ | CA2 | P00918 | 9/20 | 0.41 |
| ▸ | CA9 | Q16790 | 8/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA3 | P07451 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL987798 | 1.00 | CA1 (0.41) | CA1CA2CA9CA12CA7 | |
| SCHEMBL987423 | 1.00 | CA1 (0.41) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1276368 | 1.00 | CA1 (0.41) | CA1CA2CA9CA12CA7 | |
| SCHEMBL718849 | 0.98 | CA1 (0.40) | CA1CA2CA9CA12CA7 | |
| SCHEMBL9079331 | 0.92 | TP53 (0.38) | CA1CA2CA9CA12CA7 | |
| Ammonia Solution, Strong SCHEMBL7132558 | 0.91 | TP53 (0.37) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1276367 | 0.85 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL719166 | 0.85 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL717340 | 0.85 | CA1 (0.44) | CA1CA2CA9CA12CA7 | |
| SCHEMBL721790 | 0.85 | CA1 (0.44) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012027331-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLIC SYNDROME AND RELATED DISEASES AND DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| EP-2224932-A1 | CANCER TREATMENT USING COX-2 INHIBITOR AND ANTIMETABOLITE COMBINATIONS | Tragara Pharmaceuticals, Inc. (US) | 2010-09-08 | — | — | EP | disclosed |
| EP-2205077-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND ANTI-HER2(ERBB2) ANTIBODIES OR COMBINATIONS OF COX-2 INHIBITORS AND HER2(ERBB2) RECEPTOR TYROSINE KINASE INHIBITORS | Tragara Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009158625-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GASTROINTESTINAL DISORDERS AND GERD-RELATED RESPIRATORY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| EP-2124884-A2 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | Ironwood Pharmaceuticals, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009070547-A1 | CANCER TREATMENT USING COX-2 INHIBITOR AND ANTIMETABOLITE COMBINATIONS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009042618-A1 | THERAPIES FOR TREATING CANCER USING COMBINATIONS OF COX-2 INHIBITORS AND ANTI-HER2(ERBB2) ANTIBODIES OR COMBINATIONS OF COX-2 INHIBITORS AND HER2(ERBB2) RECEPTOR TYROSINE KINASE INHIBITORS | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2008080092-A2 | COMPOSITIONS COMPRISING BILE ACID SEQUESTRANTS FOR TREATING ESOPHAGEAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1696893-A1 | CONTINUOUS COMBINATION THERAPY WITH SELECTIVE PROSTAGLANDIN EP4, RECEPTOR AGONISTS AND AN ESTROGEN FOR THE TREATMENT OF CONDITIONS THAT PRESENT WITH LOW BONE MASS. | Pfizer Products Incorporated (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2006070406-A1 | BILAYER TABLETS OF OXCARBAZEPINE FOR CONTROLLED DELIVERY AND A PROCESS OF PREPARATION THEREOF | J.B. CHEMICALS & PHARMACEUTICALS LTD (IN) | 2006-07-06 | — | — | WO | disclosed |
| EP-1572163-A1 | CONTROLLED-RELEASE OF AN ACTIVE SUBSTANCE INTO A HIGH FAT ENVIRONMENT | Pfizer Products Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005060946-A1 | CONTINUOUS COMBINATION THERAPY WITH SELECTIVE PROSTAGLANDIN EP4, RECEPTOR AGONISTS AND AN ESTROGEN FOR THE TREATMENT OF CONDITIONS THAT PRESENT WITH LOW BONE MASS | PFIZER PRODUCTS INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1542697-A1 | MODIFIED RELEASE FORMULATIONS OF OXCARBAZEPINE AND DERIVATIVES THEREOF | Novartis AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004098562-A2 | CONTROLLED RELEASE SOLID DOSAGE NIFEDIPINE FORMULATIONS | NOVEON IP HOLDINGS CORP. (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004052343-A1 | CONTROLLED-RELEASE OF AN ACTIVE SUBSTANCE INTO A HIGH FAT ENVIRONMENT | PFIZER PRODUCTS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004026314-A1 | MODIFIED RELEASE FORMULATIONS OF OXCARBAZEPINE AND DERIVATIVES THEREOF | NOVARTIS AG (CH) | 2004-04-01 | — | — | WO | disclosed |
| EP-1313473-A2 | SUSTAINED RELEASE FORMULATIONS FOR GROWTH HORMONE SECRETAGOGUES | Pfizer Products Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002017918-A2 | SUSTAINED RELEASE FORMULATIONS FOR GROWTH HORMONE SECRETAGOGUES | PFIZER PRODUCTS INC. (GB) | 2002-03-07 | — | — | WO | disclosed |